RGD Reference Report - Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization.

Authors: Lu, F  Hu, Z  Sinard, J  Garen, A  Adelman, RA 
Citation: Lu F, etal., Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3890-6. Epub 2009 Apr 8.
RGD ID: 2312299
Pubmed: PMID:19357351   (View Abstract at PubMed)
DOI: DOI:10.1167/iovs.08-2833   (Journal Full-text)

PURPOSE: To study the efficacy and safety of factor VII (fVII)-verteporfin for targeted photodynamic therapy (TPT) compared with nontargeted photodynamic therapy (PDT) in a rat model of choroidal neovascularization (CNV). fVII-verteporfin binds tightly and specifically to tissue factor, which is expressed on endothelial cells of CNV but not normal vasculature. METHODS: Multiple CNV lesions were induced by laser photocoagulation of the retina in Brown-Norway rats. After 3 weeks, the rats were injected intravenously with fVII-verteporfin (0.5 and 1.0 mg/m(2)) or Visudyne (6.0 mg/ m(2); QLT Inc., Vancouver, BC, Canada). Randomly selected lesions were treated with a 689-nm laser 30 or 60 minutes later. The lesions were evaluated by fluorescein angiography and histopathology. RESULTS: The rats treated with Visudyne PDT showed leakage in 75% of the CNV lesions on day 7 and 100% of lesions on day 14. The rats treated with fVII-verteporfin TPT at a dose of 0.5 mg/m(2) showed leakage in 33% and 36% of the CNV lesions on days 7 and 14, respectively. When the dose was increased to 1.0 mg/m(2) for TPT, leakage was detected in 25% and 23% of the CNV lesions on days 7 and 14, respectively. No ocular side effect was detected by histopathologic evaluation. CONCLUSIONS: The frequency of leakage in CNV lesions was significantly reduced using fVII-verteporfin TPT compared with PDT. The efficacious dose with fVII-verteporfin was approximately 10% of the dose usually used in nontargeted Visudyne PDT. Using fVII-verteporfin for TPT may improve the efficacy and safety of PDT for treating choroidal neovascularization.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Choroidal Neovascularization treatmentISOF7 (Mus musculus)2312299; 2312299mouse protein in a rat modelRGD 
Choroidal Neovascularization  IDA 2312299mouse protein in a rat modelRGD 

Objects Annotated

Genes (Rattus norvegicus)
F7  (coagulation factor VII)

Genes (Mus musculus)
F7  (coagulation factor VII)

Genes (Homo sapiens)
F7  (coagulation factor VII)


Additional Information